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Abstract
Background: While INSIG2 has been reported to be associated with BMI in many populations,
conflicting results have prevented consensus over its role. In analyses of mice and cell cultures the
gene has been found to be involved in the regulation of cholesterol synthesis; however, no
relationship has been found with cholesterol metabolism in human epidemiological research.
Therefore, this study attempts to assess the effect of rs7566605 near INSIG2 on both obesity- and
cholesterol-related traits in Koreans.
Methods: The rs7566605 polymorphism was genotyped with 2,364 Koreans, and associations
with obesity- and cholesterol-related traits were analyzed statistically via an ANOVA or T-test.
Results: Replication of an association with BMI, WHR, fat mass, fat percent, and abdominal fat area
failed, and the C allele of rs7566605 was not associated significantly with total cholesterol, HDL
cholesterol, or triglyceride. However, it was found in a meta-analysis of a dominant model that the
C allele of rs7566605 appeared to affect the level of the total cholesterol, especially in female
subjects.
Conclusion: We failed to show associations of rs7566605 with cholesterol- and obesity-related
phenotypes, although we newly suggest the possible involvement of INSIG2 with the plasma level
of the total cholesterol in women.
Background
INSIG2 is considered to be a candidate gene with respect
to involvement in the development of obesity. A common
variant located 10 kb upstream of the gene, rs7566605,
was found to be associated with BMI in a recent genome-
wide association study [1]. This association has been suit-
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ably replicated in several white [1-3], African-American
[1], and Asian populations [4-6]. However, the SNP did
not have a genetic effect on obesity according to other
studies including white [2,7-14], Afro-Caribbean [12],
and Asian populations [15-17]. Hence, the INSIG2 poly-
morphism may have an important effect in overweight
populations under certain environmental circumstances,
given several positive associations found in studies of
overweight subjects [3,4].
INSIG2 has attracted the attention of researchers due to its
role in cholesterol metabolism [18]. The protein is known
to reside in the endoplasmic reticulum, where it binds to
SCAP to inhibit it from convoying SREBPs to the Golgi
apparatus [18]. Eventually, INSIG2 prevents SREBP from
activating cholesterol synthesis because SREBP cannot be
processed and activated by the Golgi enzymes. These
actions of INSIG2 were also reported in subsequent
research involving mice [18,19]. However, they have not
been confirmed in research with human populations
[4,6,8,12,13,15,20], although the prevalence of hypercho-
lesterolemia was shown to be reduced in CC homozygotes
of rs7566605 in Japanese-American women [16]. Even in
that study, the SNP was not found to be associated with
the levels of total cholesterol, HDL cholesterol, or triacylg-
lycerol.
In the present study, a replication analysis for the associa-
tion of rs7566605 with BMI as well as other obesity-
related measures was conducted using Korean popula-
tions, as controversial results have also been reported with
Asian populations. The genetic effects of INSIG2
rs7566605 on the cholesterol metabolic traits were evalu-




The Korean study population consisted of 996 subjects
recruited from an obesity clinic at the Kirin Oriental Med-
ical Hospital (Seoul, Korea) and 737 subjects recruited
from an obesity clinic at the Yeungnam University Medi-
cal Center (Daegu, Korea) [21,22]. The 996 subjects from
the Kirin obesity clinic were chosen from 1,302 individu-
als who came for help for weight control between 2001
and 2004. These subjects did not have chronic diseases,
such as hypertension, coronary artery disease, stroke, dia-
betes, and hyperlipidemia. The 737 healthy unrelated
subjects from Daegu, Korea were randomly recruited from
an unselected population that came for a routine health
check-up at Yeungnam University Hospital. These sub-
jects were not representative of the Korean general popu-
lation, as they had visited obesity clinics in order to
address weight issues and/or as they had been the healthy
selected subjects. In order to confirm this association, we
recruited 631 subjects from 12 oriental medical hospitals
in Korea (this population is hereafter named Multicenter)
for 2 years since 2007, in which 266 patients with chronic
diseases, like hypertension, hyperlipidemia, diabetes, and
stroke were removed from a total of 897 individuals. All
subjects provided written informed consent, and this
study was approved by the Institutional Review Board of
the Korea Institute of Oriental Medicine (for Kirin and
Multicenter) and Yeungnam University. With the subjects
from the Kirin Oriental Medical Hospital, additional
anthropometric features (in this case the fat mass and fat
percent) and abdominal fat mass areas were measured.
Anthropometric features were measured via bio-imped-
ance analysis using a commercial device (Inbody 2.0
Biospace, Korea). Abdominal fat areas were measured
from computerized tomography cross-sectional images
(Hispeed CT/e, GE, USA) as previously described [23,24].
Blood samples from all study subjects were drawn in the
morning after overnight fasting. They were checked for
biochemical measures of glucose, total cholesterol, trig-
lyceride, and HDL cholesterol. They were also used for
DNA extraction. The characteristics of the recruited indi-
viduals are listed in Table 1.
Genotyping
The rs7566605 SNP of the INSIG2 gene was genotyped
with TaqMan [25], according to the manufacturer's
instructions (Applied Biosystems, Foster City, CA). The
intensities of the fluorescence in the assay products were
read with Prism 7900 HT instrument (Applied Biosys-
tems). The genotyping failed in 8 individuals of the Kirin
and Yeungnam populations, therefore they were removed
in the subsequent analysis (the genotyping call rate was
99.5%.). The genotypes of the rs7566605 SNP in individ-
uals from the Multicenter population were obtained by
using the commercial Affymetrix GeneChip®  Human
Mapping 500K Array Set (Affymetrix Inc., CA, USA). The
genotyping failed in 6 individuals, and they were also
removed in the subsequent analysis (The genotyping call
rate was 99.0%.).
Statistical analyses
χ2 tests were used to determine whether the variant was in
equilibrium at its locus in the population (Hardy-Wein-
berg equilibrium). The effects of the genetic polymor-
phism on obesity-related measures and cholesterol
metabolic traits were assessed by an ANOVA for three gen-
otypes or by a T-test for the dominant and recessive mod-
els. Meta-analysis was performed to combine statistical
information from independent data sets. The results of
the meta-analysis are considered more powerful estimates
of the true effect size than those of each study. Bonferroni
correction for multiple comparisons was also performed
to remove any false positives. All statistical analyses were
performed using SAS, version 8.02 (SAS, USA) and Mat-
lab, Version 7.6 (MathWorks, Natick, MA).BMC Medical Genetics 2009, 10:96 http://www.biomedcentral.com/1471-2350/10/96
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Results
Association analyses with obesity-related measures
Replication analyses were performed for the association of
SNP rs7566605 (located 10 kb upstream of the INSIG2
transcription start site) with BMI in three Korean popula-
tions (total n = 2,634). The allele of rs7566605 was in
Hardy-Weinberg equilibrium in all three populations (P =
0.415 for Kirin; P = 0.911 for Yeungnam; P = 0.806 for
Multicenter). The each MAF of the SNP in three popula-
tions was very similar to the frequency (0.37) for the
white population [1] (0.35 for Kirin and Yeungnam pop-
ulations and 0.33 for Multicenter population; 0.37 for
white population).
Table 1: Clinical characteristics of the enrolled subjects from two obesity clinics and Multicenter hospitals
Feature n (female %) All Male Female
Kirin
Age (y) 996(93) 27.9 ± 8.43 29.3 ± 12.1 27.8 ± 8.07
BMI (Kg/m2) 996(93) 26.4 ± 4.70 32.6 ± 5.48 25.9 ± 4.27
Total cholesterol (mmol/L) 908(93) 4.92 ± 1.59 4.69 ± 1.41 4.93 ± 1.60
HDL cholesterol (mmol/L) 782(92) 1.60 ± 0.910 1.63 ± 1.29 1.59 ± 0.868
Triglyceride (mmol/L) 916(93) 1.01 ± 0.602 1.66 ± 1.09 0.963 ± 0.516
Glucose (mmol/L) 894(93) 5.63 ± 1.69 6.57 ± 2.81 5.57 ± 1.56
Yeungnam
Age (y) 737(37) 45.5 ± 11.0 43.3 ± 10.6 49.0 ± 10.8
BMI (Kg/m2) 737(37) 27.1 ± 3.44 27.4 ± 30.6 26.5 ± 3.93
Total cholesterol (mmol/L) 737(37) 5.36 ± 0.960 5.38 ± 0.955 5.32 ± 0.968
HDL cholesterol (mmol/L) 737(37) 1.37 ± 0.346 1.31 ± 0.329 1.48 ± 0.345
Triglyceride (mmol/L) 737(37) 1.81 ± 1.39 2.04 ± 1.53 1.41 ± 1.01
Glucose (mmol/L) 736(37) 5.38 ± 1.36 5.47 ± 1.57 5.21 ± 0.903
Multicenter
Age (y) 631(64) 43.4 ± 14.0 44.0 ± 13.6 42.1 ± 14.7
BMI (Kg/m2) 627(64) 23.0 ± 3.16 22.7 ± 3.24 23.4 ± 2.99
Total cholesterol (mmol/L) 600(64) 4.82 ± 0.809 4.84 ± 0.807 4.78 ± 0.815
HDL cholesterol (mmol/L) 601(64) 0.882 ± 0.0666 0.883 ± 0.0747 0.881 ± 0.0489
Triglyceride (mmol/L) 600(64) 1.31 ± 0.900 1.13 ± 0.677 1.64 ± 1.13
Glucose (mmol/L) 600(64) 5.15 ± 0.895 5.10 ± 0.803 5.25 ± 1.04
Mean ± standard deviation values are given.
Table 2: Association analyses of INSIG2 rs7566605 with BMI
n (mean ± SD)
Population Group MAF G/G G/C C/C
Kirin Total 0.35 428(26.5 ± 4.61) 432(26.3 ± 4.74) 131(26.1 ± 4.88)
PANOVA = 0.689, Pdom = 0.423, Prec = 0.564
Female 0.35 400(26.1 ± 4.41) 400(25.7 ± 3.96) 120(25.8 ± 4.82)
PANOVA = 0.311, Pdom = 0.137, Prec = 0.864
Male 0.38 28(32.0 ± 3.98) 32(34.2 ± 6.36) 11(29.7 ± 4.79)
PANOVA = 0.040, Pdom = 0. 405, Prec = 0.0525
Yeungnam Total 0.35 312(27.0 ± 3.35) 329(27.2 ± 3.57) 93(27.0 ± 3.26)
PANOVA = 0.824, Pdom = 0.751, Prec = 0.789
Female 0.34 121(26.1 ± 3.80) 119(26.8 ± 4.06) 34(26.3 ± 3.92)
PANOVA = 0.378, Pdom = 0.218, Prec = 0.837
Male 0.36 191(27.5 ± 2.93) 210(27.3 ± 3.26) 59(27.3 ± 2.78)
PANOVA = 0.765, Pdom = 0.464, Prec = 0.835
Multicenter Total 0.33 272(23.1 ± 3.31) 287(22.7 ± 2.99) 66(23.5 ± 3.24)
PANOVA = 0.161, Pdom = 0.461, Prec = 0.145
Female 0.35 168(22.9 ± 3.41) 183(22.3 ± 3.03) 47(23.4 ± 3.29)
PANOVA = 0.066, Pdom = 0.234, Prec = 0.127
Male 0.31 104(23.2 ± 3.15) 104(23.4 ± 2.81) 19(23.7 ± 3.18)
PANOVA = 0.790, Pdom = 0.581, Prec = 0.585
The P values for BMI in subjects with minor alleles were assessed by an ANOVA for a difference among three genotypes or by a T-test for the 
dominant and recessive models. The significant threshold was 0.0015 for the Kirin population (11 phenotypes and 3 different models) and 0.0033 
for the Yeungnam and Multicenter populations (5 phenotypes and 3 different models).BMC Medical Genetics 2009, 10:96 http://www.biomedcentral.com/1471-2350/10/96
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Association of the rs7566605 genotype with BMI was not
found in all three populations (Table 2). When associa-
tion analyses were extended to include other phenotypes
in relation to the considered body features (in this case the
WHR, fat mass, fat percent, total AFA, and subcutaneous
and visceral AFA), no associations were found for Koreans
(Table 3). When the population was divided into two sub-
groups according to gender (male and female), no associ-
ations were shown in either subgroup (Table 2 and Table
3). Associations with obesity-related traits were also not
found after the meta-analysis with three populations
(data not shown). Therefore, the association between
rs7566605 and BMI (as well as other obesity-related
measures) was not suitably replicated in Koreans.
Association analyses with cholesterol-related phenotypes 
and glucose
An association analysis with the plasma levels of glucose
and cholesterol-related phenotypes (i.e., total cholesterol,
HDL cholesterol, and triglyceride) was performed. No
genetic effects of the SNP were detected with the levels of
glucose, HDL cholesterol, and triglyceride. Among the
three populations, the rs7566605 C allele only appeared
to be associated with an increased level of total cholesterol
in a dominant genetic model in the Kirin population
(Table 4). When the association was analyzed for sub-
groups divided by gender, the genetic effects of the
rs7566605 seemed to be maintained in female subjects
(Table 4). When the meta-analysis was performed on the
Table 3: Association analysis of INSIG2 rs7566605 with the body features of the Kirin population
n (mean ± SD)
Group Phenotype MAF G/G G/C C/C
Total WHR 0.35 428(0.888 ± 0.0728) 432(0.885 ± 0.0776) 131(0.887 ± 0.0811)
PANOVA = 0.825, Pdom = 0.554, Prec = 0.977
Fat mass 0.35 428(24.4 ± 8.36) 432(23.8 ± 8.77) 131(23.8 ± 8.67)
PANOVA = 0.590, Pdom = 0.305, Prec = 0.689
Fat percent 0.35 428(34.3 ± 5.86) 432(33.9 ± 6.13) 131(34.2 ± 6.58)
PANOVA = 0.526, Pdom = 0.318, Prec = 0.869
Total AFA 0.35 422(293 ± 123) 430(291 ± 131) 130(280 ± 122)
PANOVA = 0.618, Pdom = 0.571, Prec = 0.344
Visceral AFA 0.35 422(65.7 ± 43.4) 430(65.5 ± 47.1) 130(60.2 ± 40.3)
PANOVA = 0.439, Pdom = 0.626, Prec = 0.164
Subcutaneous AFA 0.35 422(228 ± 98.0) 430(225 ± 103) 130(220 ± 101)
PANOVA = 0.758, Pdom = 0.569, Prec = 0.519
Female WHR 0.35 400(0.882 ± 0.0697) 400(0.875 ± 0.0664) 120(0.881 ± 0.0798)
PANOVA = 0.293, Pdom = 0.175, Prec = 0.782
Fat mass 0.35 400(23.9 ± 8.17) 400(22.9 ± 7.65) 120(23.6 ± 8.64)
PANOVA = 0.228, Pdom = 0.123, Prec = 0.845
Fat percent 0.35 400(34.5 ± 5.89) 400(33.9 ± 6.14) 120(34.5 ± 6.62)
PANOVA = 0.332, Pdom = 0.261, Prec = 0.576
Total AFA 0.35 394(285 ± 119) 398(276 ± 118) 119(277 ± 121)
PANOVA = 0.544, Pdom = 0.270, Prec = 0.742
Visceral AFA 0.35 394(607 ± 369) 398(591 ± 37.8) 119(556 ± 32.9)
PANOVA = 0.399, Pdom = 0.313, Prec = 0.192
Subcutaneous AFA 0.35 394(225 ± 97.0) 398(217 ± 95.0) 119(221 ± 102)
PANOVA = 0.533, Pdom = 0.295, Prec = 0.982
Male WHR 0.38 28(0.976 ± 0.0598) 32(1.02 ± 0.0891) 11(0.954 ± 0.0656)
PANOVA = 0.0292, Pdom = 0.192, Prec = 0.0923
Fat mass 0.38 28(31.2 ± 8.18) 32(35.0 ± 13.4) 11(26.1 ± 9.06)
PANOVA = 0.0629, Pdom = 0.589, Prec = 0.0510
Fat percent 0.38 28(32.4 ± 5.12) 32(33.9 ± 6.19) 11(30.9 ± 5.23)
PANOVA = 0.730, Pdom = 0.607, Prec = 0.207
Total AFA 0.38 28(406 ± 128) 32(473 ± 146) 11(323 ± 136)
PANOVA = 0.00778, Pdom = 0.422, Prec = 0.0120
Visceral AFA 0.38 28(135 ± 645) 32(146 ± 726) 11(110 ± 72.0)
PANOVA = 0.345, Pdom = 0.928, Prec = 0.213
Subcutaneous AFA 0.38 28(271 ± 103) 32(327 ± 139) 11(213 ± 94.3)
PANOVA = 0.0199, Pdom = 0.347, Prec = 0.0311
The P values for the AFA in subjects with minor alleles were assessed by an ANOVA for three genotypes or by a T-test for the dominant and 
recessive models. The significant threshold was 0.0015 for the Kirin population (11 phenotypes and 3 different models).BMC Medical Genetics 2009, 10:96 http://www.biomedcentral.com/1471-2350/10/96
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three populations (Kirin, Yeungnam, and Multicenter),
the rs7566605 C allele was associated in the female sub-
jects with an increased level of total cholesterol (Figure 1).
After performing a correction for multiple comparisons
with the Bonferroni correction, a significant effect could
not be found on the plasma levels of the total cholesterol
in female subgroups. However, a marginal association
was detected in the total cholesterol levels.
Discussion
INSIG2, showing involvement with cholesterol metabo-
lism in studies using the cell line and mice, has been iden-
tified as an obesity-susceptible gene in a recent whole-
genome association study [1]. However, a number of con-
trasting reports exist regarding the genetic effect of the
gene polymorphism (rs7566605) on obesity. The associa-
tion with BMI also could not be replicated in the present
research with Korean populations. The proposed relation-
ship shown in mice between INSIG2  and cholesterol
metabolism has not been verified in human studies of
white [8,12,13], African [12], Chinese [15], Japanese [4],
and Uyghur [6] populations. Our results demonstrated
that the C allele of INSIG2 rs7566605 did not significantly
affect the cholesterol levels.
However, a possible relationship was found between the
INSIG2  and the plasma level of total cholesterol in
females (Table 4). From a high-density SNP analysis in
mice, Insig2 was identified as a susceptible gene in the
control of plasma cholesterol levels [19]. Insig2 has been
strongly associated with cholesterol biosynthetic genes
that can be activated by Srebp-2 through construction of a
transcriptional network in the female liver. This implies
that the carriage of the rs7566605 C allele might weaken
the blocking of SREBP activation, leading to elevated total
cholesterol levels. However, a relationship between
rs7566605 and the cholesterol level could not be estab-
lished in the present work because there were no signifi-
cant associations in the meta-analysis and the mean level
of the total cholesterol was higher for heterozygotes than
those of the major and minor homozygotes in the Kirin
population. Therefore, it is necessary to perform an asso-
ciation analysis with other large populations and/or to do
research on the subjects who are restricted to having a
cholesterol-rich diet during a definite period in order to
elucidate the relationship and conclude whether INSIG2
is related with cholesterol metabolism in humans.
Whether INSIG2 plays a role in obesity development in
Korean subjects remains unclear, as a relationship
between rs7566605 and BMI was not found. However, an
association with obesity has been reported in many stud-
ies with white, Asian, and African populations [1-6,26].
According to the results of Cervino et al. [19], INSIG2
might be related to an increase in fat mass, as Insig2 was
identified upstream of several obesity-related genes in the
transcriptional network. This can be supported by a study
with double-knockout mice in relation to both Insig1 and
Insig2, where mice given a cholesterol-rich diet gained
more weight compared to a control group. From a recent
study, a new polymorphism, INSIG2 -102G/A, in high
linkage disequilibrium with rs7566605 (D' = 0.96 and r2
= 0.04) was found to be related to an increase in BMI and
to adipogenesis through SREBP1 activation. However, no
connection was found with triglyceride, cholesterol, or
glucose [20]. The -102G/A polymorphism has been pro-
posed as the functional polymorphism of INSIG2, as it
appears to influence the level of INSIG2  expression
directly though the weaker binding of nuclear factors on
the -102A DNA fragment. Therefore, the genetic effects of
the INSIG2 gene on fat mass accumulation can be clarified
by further studies with the new putative functional vari-
ant, and the effects may be strengthened by the habitual
ingestion of cholesterol-rich food.
Conclusion
The present study indicates there is no significant relation-
ship between the INSIG2  gene and cholesterol levels,
although the results indicate that the INSIG2 gene tended
to affect the total cholesterol level that was obtained in
this study. From human epidemiological studies con-
ducted to date, the influence of INSIG2 on body fat accu-
mulation and cholesterol metabolism is unclear.
The pooled effect sizes with 95% CIs for a total cholesterol  level in female subgroup Figure 1
The pooled effect sizes with 95% CIs for a total cho-
lesterol level in female subgroup. When the meta-analy-
sis was performed on the three populations, it was found 
that the rs7566605 SNP was associated with the total choles-
terol level in a dominant model, especially in the female sub-
group. After performing a Bonferroni correction, a significant 
effect could not be found on the plasma levels of the total 
cholesterol (significant threshold: P < 0.0033).
Effect size (95% CI) Population
Kirin (n = 840)
Yeungnam (n = 274)
Multicenter (n = 384)
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Table 4: Association analysis of INSIG2 rs7566605 with the levels of cholesterol and triglyceride
n (mean ± SD)
Group Phenotype MAF G/G G/C C/C
Kirin
Total Total cholesterol 0.35 389(4.76 ± 1.42) 395(5.12 ± 1.77) 122(4.76 ± 1.36)
PANOVA = 0.00250, Pdom = 0.0134, Prec = 0.155
HDL cholesterol 0.35 341(1.61 ± 0.907) 328(1.64 ± 0.970) 111(1.42 ± 0.701)
PANOVA = 0.0969, Pdom = 0.764, Prec = 0.0352
Triglyceride 0.35 394(1.03 ± 0.567) 398(0.968 ± 0.597) 122(1.09 ± 0.708)
PANOVA = 0.0415, Pdom = 0.117, Prec = 0.186
Female Total cholesterol 0.35 362(4.78 ± 1.44) 367(5.14 ± 1.78) 111(4.74 ± 1.34)
PANOVA = 0.00410, Pdom = 0.0170, Prec = 0.178
HDL cholesterol 0.35 314(1.64 ± 0.904) 300(1.61 ± 0.896) 100(1.41 ± 0.618)
PANOVA = 0.0647, Pdom = 0.265, Prec = 0.0203
Triglyceride 0.35 368(0.996 ± 0.537) 370(0.910 ± 0.455) 111(1.02 ± 0.613)
PANOVA = 0.0396, Pdom = 0.0877, Prec = 0.235
Male Total cholesterol 0.38 27(4.54 ± 1.10) 28(4.89 ± 1.65) 11(4.56 ± 1.47)
PANOVA = 0.629, Pdom = 0.480, Prec = 0.728
HDL cholesterol 0.39 27(1.30 ± 0.891) 28(1.95 ± 1.54) 11(1.62 ± 1.30)
PANOVA = 0.168, Pdom = 0.0804, Prec = 0.984
Triglyceride 0.38 26(1.57 ± 0.708) 28(1.73 ± 1.33) 11(1.67 ± 1.26)
PANOVA = 0.892, Pdom = 0.716, Prec = 0.875
Yeungnam
Total Total cholesterol 0.35 312 (5.35 ± 0.913) 329 (5.37 ± 0.986) 93(5.39 ± 1.03)
PANOVA = 0.930, Pdom = 0.751, Prec = 0.760
HDL cholesterol 0.35 312 (1.36 ± 0.336) 329 (1.38 ± 0.360) 93(1.37 ± 0.333)
PANOVA = 0.771, Pdom = 0.509, Prec = 0.954
Triglyceride 0.35 312 (1.83 ± 1.33) 329 (1.81 ± 1.54) 93(1.75 ± 0.996)
PANOVA = 0.802, Pdom = 0.675, Prec = 0.726
Female Total cholesterol 0.34 121(5.22 ± 0.855) 119(5.39 ± 1.04) 34(5.44 ± 1.09)
PANOVA = 0.296, Pdom = 0.124, Prec = 0.445
HDL cholesterol 0.34 121(1.49 ± 0.343) 119(1.47 ± 0.357) 34(1.51 ± 0.323)
PANOVA = 0.813, Pdom = 0.755, Prec = 0.670
Triglyceride 0.34 121(1.46 ± 1.20) 119(1.37 ± 0.883) 34(1.38 ± 0.609)
PANOVA = 0.784, Pdom = 0.610, Prec = 0.781
Male Total cholesterol 0.36 191 (5.43 ± 0.943) 210 (5.35 ± 0.956) 59 (5.36 ± 1.01)
PANOVA = 0.703, Pdom = 0.402, Prec = 0.833
HDL cholesterol 0.36 191 (1.28 ± 0.307) 210 (1.33 ± 0.353) 59 (1.29 ± 0.316)
PANOVA = 0.275, Pdom = 0.173, Prec = 0.716
Triglyceride 0.36 191 (2.06 ± 1.36) 210 (2.06 ± 1.77) 59 (1.96 ± 1.11)
PANOVA = 0.857, Pdom = 0.664, Prec = 0.850
Multicenter
Total Total cholesterol 0.34 258(4.80 ± 0.818) 277(4.80 ± 0.804) 63(4.97 ± 0.798)
PANOVA = 0.273, Pdom = 0.660, Prec = 0.107
HDL cholesterol 0.34 258(0.884 ± 0.818) 277(1.15 ± 0.293) 64(1.19 ± 0.325)
PANOVA = 0.870, Pdom = 0.625, Prec = 0.965
Triglyceride 0.34 258(1.31 ± 0.949) 277(1.35 ± 0.904) 63(1.15 ± 0.639)
PANOVA = 0.288, Pdom = 0.988, Prec = 0.133
Female Total cholesterol 0.35 159(4.81 ± 0.798) 179(4.81 ± 0.819) 46(5.03 ± 0.780)
PANOVA = 0.216, Pdom = 0.560, Prec = 0.0801
HDL cholesterol 0.35 159(0.883 ± 0.0539) 179(0.883 ± 0.0972) 47(0.879 ± 0.0161)
PANOVA = 0.943, Pdom = 0.894, Prec = 0.733
Triglyceride 0.35 159(1.18 ± 0.764) 179(1.12 ± 0.646) 46(0.99 ± 0.429)
PANOVA = 0.244, Pdom = 0.214, Prec = 0.144
Male Total cholesterol 0.31 99(4.79 ± 0.852) 98(4.77 ± 0.779) 17(4.81 ± 0.845)
PANOVA = 0.978, Pdom = 0.916, Prec = 0.883
HDL cholesterol 0.31 99(0.884 ± 0.0559) 98(0.876 ± 0.0185) 17(0.892 ± 0.102)
PANOVA = 0.336, Pdom = 0.389, Prec = 0.359
Triglyceride 0.31 99(1.52 ± 1.16) 98(1.77 ± 1.13) 17(1.57 ± 0.895)
PANOVA = 0.300, Pdom = 0.157, Prec = 0.817
The P values for the levels of cholesterol and triglyceride in subjects with minor alleles were assessed by an ANOVA for a difference among three genotypes or by 
a T-test for the dominant and recessive models. The significant threshold was 0.0015 for the Kirin population (11 phenotypes and 3 different models) and 0.0033 
for the Yeungnam and Multicenter populations (5 phenotypes and 3 different models).BMC Medical Genetics 2009, 10:96 http://www.biomedcentral.com/1471-2350/10/96
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Therefore, it is necessary to determine the roles of INSIG2
in the creation of body fat and in cholesterol metabolism,
and to elucidate the interplay among INSIG1 (another
INSIG protein), INSIG2, and the SREBP pathway on the
two metabolisms.
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